Results 181 to 190 of about 59,014 (262)

The 2025 ATS/ERS update of the international multidisciplinary classification of the interstitial pneumonias: implications for the pathologist

open access: yesHistopathology, Volume 89, Issue 3, Page 403-425, September 2026.
This review highlights changes relevant to pathologists in the updated multidisciplinary classification of interstitial pneumonias. Changes include expansion beyond idiopathic disease, subclassification as interstitial (fibrotic vs non‐fibrotic) and alveolar filling disorders, expansion to include additional patterns (e.g.
Andrew G Nicholson   +7 more
wiley   +1 more source

Myeloid/lymphoid neoplasm with FLT3 gene fusion: report of a case with a novel t(5;13)(q13;q12) SSBP2::FLT3 fusion. [PDF]

open access: yesJ Hematop
Cook JR   +6 more
europepmc   +1 more source

Intranasal Administration of Isoeugenol Improves Memory Deficits in APP/PS1 Old Mice—A Role Beyond Nrf2 Activation?

open access: yesThe FASEB Journal, Volume 40, Issue 15, 15 August 2026.
Inactivation of the Nrf2/Are pathway in AD leads to decreased antioxidant and anti‐inflammatory response and to the accumulation of beta‐amyloid (Aβ) plaques, resulting in cognitive failure. Treatment with Isoeugenol activates Nrf2, reversing these outcomes by promoting antioxidant response in neuronal cells (N2a) and by increasing the anti ...
Ana Silva   +14 more
wiley   +1 more source

MicroRNA clustering in pediatric asthma reveals differential corticosteroid responsiveness. [PDF]

open access: yesPediatr Allergy Immunol
Yang M   +8 more
europepmc   +1 more source

Prognostic Role of EMR1 in Lymph Nodes and Primary Tumors of Colon Cancer Patients

open access: yesAdvanced Biology, Volume 10, Issue 8, August 2026.
This study evaluated the prognostic value of the eosinophil biomarker EMR1 in 121 colon cancer patients. While high EMR1 levels in primary tumors correlated with improved survival, elevated levels in regional lymph nodes predicted poor outcomes. Combining EMR1 with CXCL17 further identified high‐risk patients.
Tamer Roshdy   +9 more
wiley   +1 more source

Dosing Interval Extension of Dupilumab in CRSwNP: Five‐Year Real World Outcomes

open access: yesInternational Forum of Allergy &Rhinology, Volume 16, Issue 8, Page 797-808, August 2026.
ABSTRACT Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent, often Type 2‐mediated inflammatory disease that markedly impairs quality of life. While dupilumab provides rapid improvement, there is limited evidence on long‐term outcomes beyond 2 years, and the clinical impact of dosing‐interval extension remains unclear.
Nicholas J. Campion   +15 more
wiley   +1 more source

Systemic Corticosteroids in the Management of Sinonasal Disease: An Evidence‐Based Expert Review

open access: yesInternational Forum of Allergy &Rhinology, Volume 16, Issue 8, Page 852-879, August 2026.
ABSTRACT Background Chronic rhinosinusitis (CRS) is a prevalent, heterogeneous inflammatory disease associated with significant morbidity. Systemic corticosteroids (SCS) are commonly prescribed for their anti‐inflammatory effects, but cumulative exposure carries risks, including metabolic, cardiovascular, and skeletal complications.
Andrew Thamboo   +28 more
wiley   +1 more source

Home - About - Disclaimer - Privacy